A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

İçlı, Fikri; Çeli̇k, İsmail; Aykan, Faruk; Üner, Aytu??; Demirkazık, Ahmet; Özet, Ahmet; Özgüro??lu, Mustafa; Tas, Faruk; Akbulut, Hakan; Firat, D.

doi:10.1002/(sici)1097-0142(19981215)83:12<2475::aid-cncr10>3.3.co;2-8

Cited by 11 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The epirubicin, cisplatin, and fluorouracil (ECF) regimen has been studied for a variety of gastrointestinal (GI) malignancies, including treatment of advanced and metastatic gastric cancer, 1–13 neoadjuvant and adjuvant therapy of gastric cancer, 14 treatment of advanced gastroesophageal cancer, 3,15–18 neoadjuvant and adjuvant therapy of gastroesophageal cancer, 19–23 hepatobiliary malignancies, 24–28 colorectal, 29 and small bowel tumors. 30 It has also been studied for treatment of advanced and metastatic breast cancer, 31–34 neoadjuvant therapy of breast cancer, 35–38 advanced nasopharyngeal cancer, 39 malignant dysphasia, 40 inoperable pancreatic cancer, 41 hormone-resistant prostate cancer, 42 carcinoma of unknown primary, 43 and advanced solid tumors.…”

Section: Indication(s)mentioning

confidence: 99%

Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen

Solimando¹,

Waddell²

2009

Hosp Pharm

View full text Add to dashboard Cite

show abstract

Section: Indication(s)mentioning

confidence: 99%

Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen

Solimando¹,

Waddell²

2009

Hosp Pharm

View full text Add to dashboard Cite

show abstract

Effects of natural polysaccharides on the growth and peritoneal carcinomatosis of human gastric adenocarcinoma in a nude mouse model

2006

View full text Add to dashboard Cite

Gastric cancer

Catalano¹,

Labianca

Beretta

et al. 2005

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Gastric cancer is one of the most common cancers and one of the most frequent causes of cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have undergone important changes in the last decades, but the prognosis for gastric cancer patients remains poor, especially in more advanced stages. Surgery is the mainstay of treatment of this disease, even if it is associated with a high rate of locoregional and distant recurrence. There is ongoing debate regarding the role of adjuvant treatment In advanced disease, palliation of symptoms, rather than cure, is the primary goal of patient management. Several combination therapies have been developed and have been examined in phase III trials; however, in most cases, they have failed to demonstrate a survival advantage over the reference arm. This review summarizes the most important recommendations for the management of patients with gastric cancer.

show abstract

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

Abstract: Other contributing physicians are as follows: Necdet Ü skent, M.D., from Haydarpaşa Gü lhane Mili-

Cited by 11 publications

References 0 publications

Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen

Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen

Effects of natural polysaccharides on the growth and peritoneal carcinomatosis of human gastric adenocarcinoma in a nude mouse model

Gastric cancer

Contact Info

Product

Resources

About